Semus Wealth Partners LLC Has $543,000 Stake in Merck & Co., Inc. $MRK

Semus Wealth Partners LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 36.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,862 shares of the company’s stock after acquiring an additional 1,823 shares during the quarter. Semus Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $543,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legend Financial Advisors Inc. bought a new position in Merck & Co., Inc. during the 2nd quarter valued at about $25,000. CBIZ Investment Advisory Services LLC grew its stake in Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after buying an additional 221 shares during the last quarter. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth approximately $43,000. Advantage Trust Co raised its stake in shares of Merck & Co., Inc. by 57.1% in the second quarter. Advantage Trust Co now owns 550 shares of the company’s stock valued at $44,000 after acquiring an additional 200 shares during the last quarter. Finally, Chung Wu Investment Group LLC acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $45,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the transaction, the executive vice president directly owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Trading Up 0.0%

MRK stock opened at $92.94 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $105.07. The company has a market cap of $230.69 billion, a P/E ratio of 14.32, a PEG ratio of 0.95 and a beta of 0.34. The business has a fifty day moving average of $85.43 and a 200-day moving average of $82.43.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm had revenue of $17.28 billion during the quarter, compared to analyst estimates of $17 billion. During the same period last year, the company earned $1.57 earnings per share. The company’s revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on MRK. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Morgan Stanley boosted their price objective on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research note on Monday, November 3rd. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Finally, Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $104.50.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.